ATYR: aTyr Pharma Inc Kompaniya qiymatining sof foydaga nisbati
aTyr Pharma, Inc. (ATYR) kompaniyasining joriy narxlar grafigi -0.30 ko'rsatkichini namoyish etmoqda, shu bilan birga kompaniya immun patologiyalarini davolashdagi innovator sifatida tanilgan va fibrozisga qarshi kurashi uchun pulmonologlar tomonidan yuqori baholanadi. Biznes tRNA sintetaza platformasiga tayanadi va kam uchraydigan yallig'lanish holatlariga qarshi kurashish uchun hamkorlarni jalb qilishga intiladi. Hozirda firmaning salohiyati yangi dorisining sinovlari yakuniy bosqichidan asosiy natijalarni e'lon qilish tayyorgarliklari orqali amalga oshirilmoqda.
%20P%2FE%20multiplikatori&width=1200&height=400&colorIndex=0&v=mwejrfjc.e5f-7d7lczk&start=20220704&end=20261113&filename=GURU_Markets_-_ATYR_-_aTyr-Pharma-Inc._-_PE-Multiple "ATYR: aTyr Pharma, Inc. Biznesning o‘zini qoplash muddati 06.06.2024 - 13.11.2026 | 👁️GURU.Markets👁️")
aTyr (ATYR) kompaniyasining tahliliy kesimlari
- narx va narxlar bo'yicha konsensus prognoz:
- bozor kapitallashuvi haqida ma'lumot:
- buxgalteriya balansi bo'yicha sof aktivlar qiymati ko'rsatkichlari:
- qarzlar va to'lov qobiliyati haqida ma'lumot:
Umumiy qarzning xususiy kapitalga nisbati aTyr Pharma, Inc.|ATYR - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning kapitalga nisbati aTyr Pharmaceuticals|ATYR - Kompaniya qarzlari|Qarzning balans qiymatiga nisbati aTyr Pharma, Inc.|ATYR - Kompaniyaning uzoq muddatli qarzlari|Qisqa muddatli qarz aTyr Pharma|Tezkor likvidlik koeffitsiyenti atyrpharma.com
- foyda va bozor multiplikatorlari tafsilotlari:
ATYR - Sof daromad|Kelajakdagi sof foyda aTyr Pharma, Inc.|ATYR - Narx-foyda koeffitsiyenti|Prognoz qilingan narx-foyda nisbati aTyr Pharma Inc|ATYR - Narxning foydaga va o‘sish sur’atiga nisbati|Biznes qiymatining amortizatsiya chegirilishidan oldingi operatsion foydaga nisbati aTyr Pharma, Inc.|ATYR - Eskirish chegirilmasdan oldingi operatsion foyda|Sirpanuvchi yil uchun bir aksiya uchun foyda aTyr Pharma|ATYR - So'nggi o'n ikki oy davomida bir aksiya uchun foyda|So'nggi o'n ikki oy davomida bir aksiya uchun sof foydaning yillik dinamikasi atyrpharma.com|ATYR - Joriy yilda foyda o'sishi|Keyingi yilda bir aksiya uchun foydaning kutilayotgan dinamikasi aTyr Pharma, Inc.
- realizatsiya hajmi va tushum ko'rsatkichlari:
Kompaniyaning har tomonlama tahlili:atyrpharma.com ATYR
P/E koeffitsiyenti biznesning bozor qiymatini uning sof foydasiga nisbatan o'lchaydi, bu esa investorlarga aktivning haddan tashqari qimmat baholanganlik darajasini aniqlash va adolatli kapitalizatsiya darajasini baholash imkonini beradi. aTyr Pharma, Inc. (ATYR) kompaniyasining narx-foyda dinamikasini tahlil qilish orqali investor biotexnologiya sohasining o'ziga xos jihatlarini kuzatadi: minimal ekologik iz va laboratoriya protokollariga e'tibor foydani beqaror qiladi, bu esa ushbu ko'rsatkichni narxlarning kritik darajada qizib ketishiga qarshi filtrga aylantiradi.
Muhim raqobatchilar
P/E multiplikatori argenx.com|Narx-foyda koeffitsiyenti BNTX (BioNTech)|ABVX (ABIVAX) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori ADMA (ADMA Bio)|Biznesning o‘zini qoplash muddati Protagonist Corp (PTGX)|IMVT - Narxning foydaga nisbati|kiniksa.com (KNSA) - Narx-foyda koeffitsiyenti|Grifols (GRFS) - Narxning foydaga nisbati|Narx-foyda koeffitsiyenti Adaptive Biotech|Narx-foyda koeffitsiyenti CLDX|P/E multiplikatori Aurinia Corp|Narxning foydaga nisbati BioCryst (BCRX)|veratx.com - Narx-foyda multiplikatori|P/E multiplikatori DNTH (Dianthus Therapeutics, Inc.)|Pharvaris NV (PHVS) - Kapitalizatsiyaning foydaga nisbati|AbCellera Bio - P/E multiplikatori|TRML - P/E multiplikatori|PGEN (Precigen, Inc.) - Narx-foyda koeffitsiyenti|PHAR: Bozor narxining sof foydaga nisbati|Narx-foyda koeffitsiyenti NKTR|Kapitalizatsiyaning foydaga nisbati Upstream Bio, Inc. UPB|Narxning foydaga nisbati Zenas Biopharma, Inc. (ZBIO)|IMNM (Immunome Bio) - Kompaniya qiymatining sof foydaga nisbati|Gossamer Bio, Inc. - Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati KALV|SEPN - Narxning foydaga nisbati|Kapitalizatsiyaning sof foydaga nisbati PVLA|SVRA: P/E multiplikatori|Rigel Corp - Kompaniya qiymatining sof foydaga nisbati|ANAB (AnaptysBio, Inc.) - P/E multiplikatori|P/E multiplikatori astriatx.com|Narxning foydaga nisbati enGene (ENGN)|RAPT (RAPT Therapeutics Inc.) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Aerovate Therapeutics JBIO|ACRS - Narx-foyda koeffitsiyenti|Kyverna Therapeutics - P/E multiplikatori|TLSA - P/E multiplikatori|CABA (Cabaletta Bio) - Narx-foyda koeffitsiyenti|Ventyx Biosciences Inc. - Kompaniya qiymatining sof foydaga nisbati|THTX (Theratechnologies Inc) - P/E multiplikatori|Avalo Therapeutics Inc (AVTX) - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati Eledon Pharmaceuticals (ELDN)|agenusbio.com - Narx-foyda multiplikatori|P/E multiplikatori CLYM (Climb Bio)|ZURA - Narx-foyda koeffitsiyenti|ADAG: Narx-foyda koeffitsiyenti|Biznesning o‘zini qoplash muddati ImageneBio Inc IMA|STTK: P/E multiplikatori|Equillium (EQ) - P/E multiplikatori|Narx-foyda koeffitsiyenti CNTB|IMUX (Immunic Inc) - Bozor narxining sof foydaga nisbati|Narx-foyda koeffitsiyenti ATRA (Atara Biotherapeutics)|IFRX - Kapitalizatsiyaning foydaga nisbati|Narxning foydaga nisbati X4 Pharmaceuticals XFOR|Kompaniya qiymatining sof foydaga nisbati ACET|CELU - Narxning foydaga nisbati|Kapitalizatsiyaning sof foydaga nisbati INMB|BRNS: P/E multiplikatori|Kezar Life Sciences Inc - Kompaniya qiymatining sof foydaga nisbati|SABS (SAB Biotherapeutics) - P/E multiplikatori|P/E multiplikatori akaritx.com|Narxning foydaga nisbati Enlivex Therapeutics (ENLV)|QTTB (q32bio.com) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati GeoVax Labs Inc GOVX|EDSA - Narx-foyda koeffitsiyenti|iBio, Inc. - P/E multiplikatori|CARM - P/E multiplikatori|XTLB (XTL Biopharmaceuticals Ltd.) - Narx-foyda koeffitsiyenti|Bolt Biotherapeutics, Inc. - Kompaniya qiymatining sof foydaga nisbati|HCWB (HCW Biologics, Inc.) - P/E multiplikatori|Aptevo (APVO) - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati AIM ImmunoTech Inc. (AIM)|Narx-foyda koeffitsiyenti aditxt.com ADTX|Narxning foydaga nisbati GRI Bio GRI|XRTX - Narx-foyda koeffitsiyenti|HIND: Narx-foyda koeffitsiyenti|REVB - P/E multiplikatori|Indaptus Therapeutics (INDP) - Narxning foydaga nisbati|Narx-foyda multiplikatori SCNI|CALI (CalciMedica Inc) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Affimed Therapeutics AFMD|P/E multiplikatori ALLK|P/E multiplikatori hookipapharma.com (HOOK)|IGM Biosciences - Narx-foyda koeffitsiyenti|Bozor narxining sof foydaga nisbati ITOS (iteostherapeutics.com)|OCEA: Narx-foyda koeffitsiyenti|Kapitalizatsiyaning foydaga nisbati TC BioPharm (Holdings) Plc|Third Harmonic Bio, Inc (THRD) - Narxning foydaga nisbati
